Peer Exchange
Our Peer Exchange™ program provides a multi-stakeholder perspective on important issues that providers, pharmacists, payers, and patients grapple with as they step into the world of biosimilars.
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH, conclude the Peer ExchangeTM with a discussion of the importance of putting patients at the center of the biosimilar conversation.
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH, discuss how biosimilars are making a difference to patients in terms of cost and access.
Christy M. Gamble, JD, DrPH, MPH, addresses the need for diversity in clinical trials.
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH talk about diversity, or the lack thereof, in clinical trials and the ramifications that a lack of diversity has for patients.
Amanda Forys, MSPH, and Christy M. Gamble, JD, DrPH, MPH, weigh the question of whether manufacturers' patient assistance programs are doing enough to address high drug costs.
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH, share their thoughts about patient assistance programs for high-cost drugs.
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH, examine whether the changes CMS has made this year will incentivize private payers to encourage biosimilar use, and discuss pharmacy-level substitution of biosimilars for reference biologics.
Amanda Forys, MSPH and Christy M. Gamble JD, DrPH, MPH, discuss CMS’ recent changes to reimbursement for biosimilars, and the impacts that these changes will have on patients under Medicare Part B and Part D.
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH address the pros and cons of multiple scenarios regarding rebates.
Christy M. Gamble, JD, DrPH, MPH, and Amanda Forys, MSPH, discuss what patients are paying for biologics and biosimilars, and how cost affects access.
